Company Filing History:
Years Active: 2021-2025
Title: Yiping Rong: Innovator in Monoclonal Antibodies
Introduction
Yiping Rong is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a total of two patents to his name, his work focuses on innovative treatments for various diseases.
Latest Patents
Yiping Rong's latest patents include groundbreaking research on antibodies binding to CTLA-4. These patents disclose isolated monoclonal antibodies that comprise a CD152-binding domain, specifically targeting human CD152. The methods outlined in these patents provide new avenues for treating diseases, including cancers and autoimmune disorders.
Career Highlights
Throughout his career, Yiping Rong has worked with notable companies such as Harbour Biomed (Shanghai) Co., Ltd. and Harbour Biomed Co., Ltd. His expertise in monoclonal antibodies has positioned him as a key figure in the biotechnology sector.
Collaborations
Yiping has collaborated with talented individuals in his field, including Xin Gan and Yun He. These partnerships have further enhanced his research and development efforts.
Conclusion
Yiping Rong's innovative work in monoclonal antibodies represents a significant advancement in medical science. His contributions have the potential to improve treatment options for patients suffering from serious diseases.